RecruitingNCT03979170
Patient-derived Organoids of Lung Cancer to Test Drug Response
Sponsor
University Hospital, Geneva
Enrollment
50 participants
Start Date
Apr 1, 2019
Study Type
OBSERVATIONAL
Conditions
Summary
This is a single center, single arm, open and exploratory clinical study, with 50 cases planned for a period of 3 years. The purpose of this study is to evaluate the consistency and accuracy of a Patient-Derived Organoid (PDO) Model of lung cancer to predict the clinical efficacy of anti-cancer drugs, in order to predict the best chemotherapy regimen for each given patient.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Histologically proven lung cancer
- Age ≥ 18
- Written informed and signed consent
- Accessible to biopsy and/or surgery sample of metastasis and/or primitive tumour
Exclusion Criteria4
- Less than 18 years of age
- Not able to give informed consent (language, intellectual capacities, etc.)
- Not accessible to biopsy and/or surgery sample
- Not enough lung tissue for a histological analysis or the remaining lung tissue is not enough to perform a routine pathological analysis.
Interventions
PROCEDURELung tumor resection
lung tumor resection
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03979170
Related Trials
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
NCT046786483 locations
Virtual Agent Feasibility in Oncology Patients (NTT Data)
NCT066820131 location
Lung Cancer Screening in HIgh Risk nonsmokErs by Artificial inteLligence Device
NCT062954971 location
Study of Novel Treatment Combinations in Patients With Lung Cancer
NCT05633667100 locations
Empathic Communication Skills (ECS) Training
NCT0545684112 locations